Pfizer has successfully completed its acquisition of Metsera for $7 billion, with plans to integrate Metsera’s metabolic-disease pipeline into its own portfolio. This move follows a lengthy negotiation process and reflects Pfizer’s strategic investment in high-growth therapeutic areas, as emphasized by CEO Albert Bourla. The acquisition includes promising candidates like MET-097i and MET-233i, aimed at advancing treatment options in metabolic diseases. Following the deal, Metsera will become a fully owned subsidiary of Pfizer, with its shares ceasing to trade on NASDAQ. The transaction is expected to have a dilutive impact on Pfizer’s finances through 2030, with updates to its financial outlook anticipated later this year.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://manufacturingchemist.com/pfizer-completes-10bn-acquisition-of-metsera-glp-1
